NextCure, Inc. (NASDAQ:NXTC – Get Free Report) major shareholder Adar1 Capital Management, Llc acquired 36,303 shares of NextCure stock in a transaction on Friday, July 31st. The stock was purchased at an average cost of $4.94 per share, with a total value of $179,336.82. Following the completion of the transaction, the insider directly owned 722,419 shares in the company, valued at $3,568,749.86. This represents a 5.29% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Adar1 Capital Management, Llc also recently made the following trade(s):
- On Thursday, July 30th, Adar1 Capital Management, Llc bought 292,850 shares of NextCure stock. The shares were purchased at an average cost of $4.93 per share, for a total transaction of $1,443,750.50.
- On Wednesday, July 29th, Adar1 Capital Management, Llc bought 3,410 shares of NextCure stock. The shares were purchased at an average cost of $5.00 per share, for a total transaction of $17,050.00.
- On Tuesday, July 28th, Adar1 Capital Management, Llc bought 6,400 shares of NextCure stock. The stock was acquired at an average price of $4.95 per share, for a total transaction of $31,680.00.
- On Monday, July 27th, Adar1 Capital Management, Llc bought 7,798 shares of NextCure stock. The stock was acquired at an average cost of $5.00 per share, with a total value of $38,990.00.
NextCure Stock Up 31.4%
NXTC stock opened at $5.78 on Wednesday. The firm has a market cap of $20.87 million, a PE ratio of -0.34 and a beta of 1.27. The business has a 50 day moving average of $3.39 and a 200-day moving average of $8.54. NextCure, Inc. has a 12-month low of $1.55 and a 12-month high of $15.74.
Wall Street Analysts Forecast Growth
A number of research firms recently issued reports on NXTC. Wall Street Zen downgraded shares of NextCure from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Zacks Research upgraded shares of NextCure from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 11th. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of NextCure in a report on Wednesday, July 15th. Finally, Weiss Ratings lowered NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 7th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $19.00.
Read Our Latest Stock Report on NextCure
Institutional Trading of NextCure
A number of institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its holdings in NextCure by 18.6% during the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock valued at $329,000 after buying an additional 3,636 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of NextCure by 18.7% in the fourth quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after acquiring an additional 5,300 shares during the period. Marshall Wace LLP bought a new position in shares of NextCure in the fourth quarter valued at approximately $160,000. Millennium Management LLC purchased a new position in NextCure during the fourth quarter valued at approximately $185,000. Finally, Affinity Asset Advisors LLC grew its stake in NextCure by 28.9% during the fourth quarter. Affinity Asset Advisors LLC now owns 247,294 shares of the company’s stock valued at $3,509,000 after acquiring an additional 55,412 shares in the last quarter. Hedge funds and other institutional investors own 42.65% of the company’s stock.
NextCure Company Profile
NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.
The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.
Read More
- Five stocks we like better than NextCure
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.
